Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 12:7:181-97.
doi: 10.4137/CMO.S8528. eCollection 2013.

Update on optimal management of acute myeloid leukemia

Fuad El Rassi  1 , Martha Arellano
Affiliations

Update on optimal management of acute myeloid leukemia

Fuad El Rassi et al. Clin Med Insights Oncol. .

Abstract

Acute myeloid leukemia (AML) represents a malignant accumulation of immature myeloid cells in the marrow, presenting with impaired hematopoiesis and its attendant complications, including bleeding, infection, and organ infiltration. Chromosomal abnormalities remain the most powerful predictors of AML prognosis and help to identify a subgroup with favorable prognosis. However, the majority of AML patients who are not in the favorable category succumb to the disease. Therefore, better efforts to identify those patients who may benefit from more aggressive and investigational therapeutic approaches are needed. Newer molecular markers aim at better characterizing the large group of intermediate-risk patients and to identify newer targets for therapy. A group that has seen little improvement over the years is the older AML group, usually defined as age ≥ 60. Efforts to develop less intensive but equally efficacious therapy for this vulnerable population are underway.

Keywords: AML; management; prognosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proposed algorithm for newly-diagnosed AML. Note: *= 7 + 3 or modified HiDAC induction.
See this image and copyright information in PMC

References

    1. National Cancer Institute. SEER Stat Fact Sheets: Acute Myeloid Leukemia, 1975–2009. [Accessed Apr 16, 2013]. Available at http://seer.cancer.gov/statfacts/html/amyl.html#incidence-mortality.
    1. Rowe JM. Optimal induction and post-remission therapy for AML in first remission. Hematology Am Soc Hematol Educ Program. 2009:396–405. - PubMed
    1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33(4):451–8. - PubMed
    1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292–302. - PubMed
    1. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92(7):2322–33. - PubMed